Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...

Vicki DeArmon launched Foghorn Press and Sibylline Press, and has now written an “almost true” memoir of San Francisco’s ...

A malfunctioning foghorn has been blaring every 30 seconds off the coast of a Narragansett, Rhode Island, beach for the last few weeks. Narragansett residents spoke to NBC 10 about the relentless ...

March 06, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting ...

Jake Peavy is returning to where his career began. 2014 SF Giants World Series champion Jake Peavy has joined the San Diego Padres front office as a special ass ...

Though the neighborhood is normally relatively peaceful, Mainville said the malfunctioning foghorn at the end of the jetty is testing his nerves. “Over and over and over,” he said.

Foghorn Therapeutics Inc. announced continued enrollment in its Phase 1 trial for FHD-909, a first-in-class oral selective SMARCA2 inhibitor targeting SMARCA4 mutated cancers, particularly non ...

These are among the new titles released by Bay Area and Northern California writers, listed in alphabetical order by author ...